We linked health insurance records to cancer registry data to analyze colony-stimulating factor use, finding wide divergence from that recommended by practice guidelines. Objective: To examine ...
Experimental studies and early-phase clinical trials suggest that mobilization of bone marrow stem cells by granulocyte-colony-stimulating factor (G-CSF) can be used to improve cardiac regeneration ...
The effects of sargramostim and filgrastim on hematopoietic cells are described. Filgrastim is a lineage-specific colonystimulating factor (CSF), mainly affecting neutrophils. In addition to enhancing ...
These observations suggest that G-CSF-mediated mobilization of bone marrow stem cells may enhance myocyte regeneration. However, the mobilized bone marrow cells could also have direct cytokine effects ...
Although currently underutilized, granulocyte colony-stimulating factor prophylaxis as supportive cancer care provides substantial value to society. Aligning utilization with clinical guidelines would ...
A retrospective cohort study design was used to analyze commercial claims data in adults with lung cancer initiated on chemotherapy from April 1, 2013, to March 30, 2015. The tool was implemented at ...
Granulocyte colony-stimulating factor (G-CSF), which causes division and differentiation of bone marrow cells depending on the body's need for leukocytes, has a significant regulatory effect not only ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 77, No. 9, [Part 2: Biological Sciences] (Sep., 1980), pp. 5346-5350 (5 pages) Granulocyte-macrophage ...
29 Phase I Stage III/IV melanoma pts (16) Intradermal injection of sargramostim into melanoma lesions and normal skin (as a control) for 10 days at four dose levels (10, 20, 40, and 80 µg/day) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback